Related Experiment Videos
Commentary on 'Alpha calculus in clinical trials: considerations and commentary for the new millennium'
1Food and Drug Administration, Center for Drug Evaluation and Review, Office of Biostatistics, 5600 Fishers Lane, Parklawn Building, Room 15B-45, Rockville, MD 20857, USA.
Statistics in Medicine
|March 29, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Clinical pharmacology and therapeutics·2013
The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
Clinical pharmacology and therapeutics·2012
FDA's critical path initiative: a perspective on contributions of biostatistics.
Biometrical journal. Biometrische Zeitschrift·2006
Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance.
Controlled clinical trials·1997
A Bayesian Spatiotemporal Model for Joint Estimation of Brain Activation and Connectivity in fMRI Studies.
Statistics in medicine·2026
Nonparametric Assessment of the Calibration of Individualized Treatment Effects.
Statistics in medicine·2026
Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models.
Statistics in medicine·2026
Bayesian Machine Learning for Estimating Optimal Dynamic Treatment Regimes With Ordinal Outcomes.
Statistics in medicine·2026
Shape-Based Partially Linear Single-Index Cox Model for Alzheimer's Disease Conversion.
Statistics in medicine·2026
Local Linear Estimation for Covariate-Dependent Coefficients Model in Disease Mapping.
Statistics in medicine·2026
Formica: Lacan, Rizzolo, and My Approach to Countertransference.
Journal of the American Psychoanalytic Association·2026